Cancer immunoediting and immune dysregulation in multiple myeloma
- 10 December 2020
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 136 (24), 2731-2740
- https://doi.org/10.1182/blood.2020006540
Abstract
Avoiding immune destruction is a hallmark of cancer. Over the past few years, significant advances have been made in understanding immune dysfunction and immunosuppression in multiple myeloma (MM), and various immunotherapeutic approaches have delivered improved clinical responses. However, it is still challenging to completely eliminate malignant plasma cells (PCs) and achieve complete cure. The interplay between the immune system and malignant PCs is implicated throughout all stages of PC dyscrasias, including asymptomatic states called monoclonal gammopathy of undetermined significance and smoldering myeloma. Although the immune system effectively eliminates malignant PCs, or at least induces functional dormancy at early stages, malignant PCs eventually evade immune elimination, leading to progression to active MM, in which dysfunctional effector lymphocytes, tumor-educated immunosuppressive cells, and soluble mediators coordinately act as a barrier for antimyeloma immunity. An in-depth understanding of this dynamic process, called cancer immunoediting, will provide important insights into the immunopathology of PC dyscrasias and MM immunotherapy. Moreover, a growing body of evidence suggests that, together with nonhematopoietic stromal cells, bone marrow (BM) immune cells with unique functions support the survival of normal and malignant PCs in the BM niche, highlighting the diverse roles of immune cells beyond antimyeloma immunity. Together, the immune system critically acts as a rheostat that fine-tunes the balance between dormancy and disease progression in PC dyscrasias.Keywords
This publication has 123 references indexed in Scilit:
- Bone marrow and the control of immunityCellular & Molecular Immunology, 2011
- Sustained antibody responses depend on CD28 function in bone marrow–resident plasma cellsThe Journal of Experimental Medicine, 2011
- Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell nicheThe Journal of Experimental Medicine, 2011
- First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialThe Lancet, 2010
- Elevated IL-17 produced by Th17 cells promotes myeloma cell growth and inhibits immune function in multiple myelomaBlood, 2010
- Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic TargetCancer Cell, 2009
- MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myelomaProceedings of the National Academy of Sciences, 2008
- Vasculogenic mimicry by bone marrow macrophages in patients with multiple myelomaOncogene, 2007
- Frequent and specific immunity to the embryonal stem cell–associated antigen SOX2 in patients with monoclonal gammopathyThe Journal of Experimental Medicine, 2007
- Bone marrow mesenchymal stem cells are abnormal in multiple myelomaLeukemia, 2007